Estradiol

Vivelle is used to treat moderate to severe vasomotor symptoms associated with menopause, including hot flashes and night sweats. It may also be prescribed for vaginal atrophy and as prevention of postmenopausal osteoporosis. In some cases, it is used for estrogen deficiency due to hypogonadism, castration, or primary ovarian insufficiency.

Vivelle contains estradiol, a synthetic form of the primary female sex hormone estrogen. As a transdermal patch, it delivers a consistent dose of estradiol through the skin and into the bloodstream, supplementing the body's declining estrogen production after menopause or following ovary removal.

Vivelle contains estrogen and should not be used during pregnancy. Treatment should begin with the lowest effective dose for the shortest duration consistent with treatment goals. Estrogen-only therapy increases endometrial cancer risk; progestin may be added for women with an intact uterus. Common side effects include skin irritation at the patch site, breast tenderness, headache, and mood changes. Risk assessment should consider cardiovascular health, breast cancer history, and other factors before initiating therapy.